Table A5.
Residual Masses at the End of Treatment
| Residual Masses at the End of Chemotherapy | Treatment |
Total (N = 337) |
||||
|---|---|---|---|---|---|---|
| BEP (n = 169) |
T-BEP (n = 168) |
|||||
| No. of Patients | % | No. of Patients | % | No. of Patients | % | |
| No residual masses | 22 | 13.0 | 14 | 8.3 | 36 | 10.7 |
| Residual masses | 134 | 79.3 | 135 | 80.4 | 269 | 79.8 |
| Residual masses in nonseminoma or mixed seminoma/nonseminoma patients | 123 | 126 | 249 | |||
| No response form | 13 | 7.7 | 19 | 11.3 | 32 | 9.5 |
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; T-BEP, paclitaxel–bleomycin, etoposide, and cisplatin.